M.E. Allison & Co., Inc. Gilead Sciences, Inc. Transaction History
M.E. Allison & Co., Inc.
- $144 Billion
- Q3 2025
A detailed history of M.E. Allison & Co., Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, M.E. Allison & Co., Inc. holds 3,633 shares of GILD stock, worth $450,818. This represents 0.28% of its overall portfolio holdings.
Number of Shares
3,633
Previous 3,633
-0.0%
Holding current value
$450,818
Previous $403 Million
0.12%
% of portfolio
0.28%
Previous 0.32%
Shares
1 transactions
Others Institutions Holding GILD
# of Institutions
2,371Shares Held
1.01BCall Options Held
8.63MPut Options Held
7.39M-
Black Rock Inc. New York, NY121MShares$15 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.8 Billion0.21% of portfolio
-
State Street Corp Boston, MA59.1MShares$7.33 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA45.2MShares$5.61 Billion0.72% of portfolio
-
Dodge & Cox San Francisco, CA30.1MShares$3.74 Billion1.93% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $156B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...